DS-7300a, a DNA Topoisomerase I Inhibitor, DXd-Based Antibody–Drug Conjugate Targeting B7-H3, Exerts Potent Antitumor Activities in Preclinical Models

B7-H3 is overexpressed in various solid tumors and has been considered as an attractive target for cancer therapy. Here, we report the development of DS-7300a, a novel B7-H3–targeting antibody–drug conjugate with a potent DNA topoisomerase I inhibitor, and its in vitro profile, pharmacokinetic profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamato, Michiko, Hasegawa, Jun, Maejima, Takanori, Hattori, Chiharu, Kumagai, Kazuyoshi, Watanabe, Akiko, Nishiya, Yumi, Shibutani, Tomoko, Aida, Tetsuo, Hayakawa, Ichiro, Nakada, Takashi, Abe, Yuki, Agatsuma, Toshinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Large Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377751/
https://www.ncbi.nlm.nih.gov/pubmed/35149548
http://dx.doi.org/10.1158/1535-7163.MCT-21-0554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9377751/
https://www.ncbi.nlm.nih.gov/pubmed/35149548
http://dx.doi.org/10.1158/1535-7163.MCT-21-0554

Ejemplares similares